RightFit Trial Directory

Lung Cancer clinical trials in Boston, MA

75 recruiting lung cancer studies with a site in Boston, MA.

All trials in Boston, MA · All Lung Cancer trials

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

Boston, MA · +39 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Beverly, MA · Boston, MA · +1147 more sites

RecruitingPhase 1 / Phase 2NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Sponsor: Revolution Medicines, Inc.

Boston, MA · +28 more sites

RecruitingPhase 1NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Sponsor: Eli Lilly and Company

Boston, MA · +22 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Boston, MA · +52 more sites

RecruitingPhase 1 / Phase 2NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Sponsor: Tango Therapeutics, Inc.

Boston, MA · +14 more sites

RecruitingPhase 1 / Phase 2NCT07038343

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Sponsor: Avenzo Therapeutics, Inc.

Boston, MA · +18 more sites

RecruitingPhase 1NCT03460977

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Sponsor: Pfizer

Boston, MA · Newton, MA · +42 more sites

RecruitingPhase 1 / Phase 2NCT07020221

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Sponsor: Verastem, Inc.

Boston, MA · +12 more sites

RecruitingPhase 1 / Phase 2NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier

Boston, MA · +20 more sites

RecruitingPhase 1 / Phase 2NCT07070232

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Sponsor: BioNTech SE

Boston, MA · +17 more sites

RecruitingPhase 2 / Phase 3NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Sponsor: Bristol-Myers Squibb

Boston, MA · +27 more sites

RecruitingPhase not listedNCT00471978

DNA Analysis of Blood and Tissue From Patients With Lung Cancer

Sponsor: Massachusetts General Hospital

Boston, MA

RecruitingPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Sponsor: Genmab

Boston, MA · +35 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Boston, MA · Burlington, MA · +85 more sites

RecruitingPhase 2NCT05967689

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Sponsor: Taiho Oncology, Inc.

Boston, MA · +17 more sites

RecruitingPhase 1 / Phase 2NCT06780137

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Sponsor: Merck Sharp & Dohme LLC

Boston, MA · +8 more sites

RecruitingPhase 2NCT07492680

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Sponsor: Bristol-Myers Squibb

Boston, MA · +15 more sites

RecruitingPhase 1 / Phase 2NCT05797168

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Sponsor: AstraZeneca

Boston, MA · +12 more sites

RecruitingNot applicableNCT07059884

Distance-Based Exercise to Preserve Function and Prevent Disability

Sponsor: Alliance for Clinical Trials in Oncology

Boston, MA · +22 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

Boston, MA · +37 more sites

RecruitingPhase 1NCT05877599

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Sponsor: AstraZeneca

Boston, MA · +18 more sites

RecruitingPhase 1NCT07578571

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Sponsor: Immunome, Inc.

Boston, MA · +3 more sites

RecruitingPhase 1NCT06218914

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Sponsor: AstraZeneca

Boston, MA · +17 more sites

RecruitingPhase 1NCT07037758

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Sponsor: Amgen

Boston, MA · +12 more sites

RecruitingPhase 1 / Phase 2NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Sponsor: Neonc Technologies, Inc.

Boston, MA · +7 more sites

RecruitingPhase 3NCT06357533

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Sponsor: AstraZeneca

Boston, MA · +61 more sites

RecruitingPhase 2 / Phase 3NCT07063745

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Sponsor: Bristol-Myers Squibb

Boston, MA · +43 more sites

RecruitingPhase 1NCT07006727

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Sponsor: Novartis Pharmaceuticals

Boston, MA · +3 more sites

RecruitingPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sponsor: SystImmune Inc.

Boston, MA · +20 more sites

RecruitingPhase 1 / Phase 2NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Sponsor: Blueprint Medicines Corporation

Boston, MA · +9 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Boston, MA · Brighton, MA · Foxborough, MA · +94 more sites

RecruitingPhase 2NCT06855771

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Sponsor: Bristol-Myers Squibb

Boston, MA · +9 more sites

RecruitingPhase 2NCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Sponsor: Reunion Neuroscience Inc

Boston, MA · Worcester, MA · +30 more sites

RecruitingPhase not listedNCT05059444

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Sponsor: Guardant Health, Inc.

Boston, MA · +32 more sites

RecruitingPhase 2NCT04899908

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Sponsor: Brigham and Women's Hospital

Boston, MA

RecruitingPhase 2NCT07130786

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

Sponsor: Ayal A. Aizer, MD

Boston, MA

RecruitingPhase 2NCT07132190

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

Sponsor: Ayal A. Aizer, MD

Boston, MA

RecruitingPhase 1 / Phase 2NCT07491497

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Sponsor: TRIANA Biomedicines, Inc.

Boston, MA · +12 more sites

RecruitingPhase 1 / Phase 2NCT04165070

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Sponsor: Merck Sharp & Dohme LLC

Boston, MA · +16 more sites

RecruitingPhase not listedNCT07600801

LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B

Sponsor: Massachusetts General Hospital

Boston, MA

RecruitingPhase 1NCT06586515

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Sponsor: Eli Lilly and Company

Boston, MA · +23 more sites

RecruitingPhase 1 / Phase 2NCT04683250

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Sponsor: Taiho Pharmaceutical Co., Ltd.

Boston, MA · +8 more sites

RecruitingPhase 1 / Phase 2NCT05592626

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Sponsor: Marengo Therapeutics, Inc.

Boston, MA · +12 more sites

RecruitingNot applicableNCT06026111

Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial

Sponsor: Dana-Farber Cancer Institute

Boston, MA

RecruitingPhase 3NCT06203210

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Sponsor: Daiichi Sankyo

Boston, MA · +29 more sites

RecruitingPhase 1 / Phase 2NCT06706076

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Sponsor: BlossomHill Therapeutics

Boston, MA · +21 more sites

RecruitingPhase 1NCT06562192

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Sponsor: Novartis Pharmaceuticals

Boston, MA · +8 more sites

RecruitingPhase 1NCT06179160

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Sponsor: Incyte Corporation

Boston, MA · +12 more sites

RecruitingPhase 1 / Phase 2NCT05098132

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Sponsor: Synthekine

Boston, MA · +30 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.